CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Sinntaxis is developing SIN020, a drug aimed at aiding recovery in stroke patients by targeting glutamate receptors. This project focuses on preparing for clinical trials to validate the drug's effectiveness in restoring neurological function post-stroke.
The aim of this project is to develop a business plan to guide clinical development and commercialisation of SIN020; a glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) to promote recovery of the injured stroke brain.
Every year, 1 million people in Europe have a stroke and the healthcare and non-healthcare cost is estimated at EUR 45 billion.
The only treatment option available for restoring neurological function in stroke patients is rehabilitation, which has limited effect. S…
SINNTAXIS AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
